tbuckley/cabot-search huggingface dataset:
Abstract 04: Precise recruitment for precision oncology: RWD use for feasibility and patient identification
Authors: Sivakumar Gowrisankar, Angela Qu
Journal: Clinical Cancer Research (2020)

Abstract Mesenchymal-epithelial transition (MET), that encodes c-MET receptor, is a proto-oncogene tyrosine kinase that is involved in a variety of cell-signaling pathways. In normal cells, MET is activated by hepatocyte growth factor (HGF) and is involved in the control of tissue homeostasis. In cancer cells, abnormal MET signaling is associated with angiogenesis and progression. Several activating mutations, including MET gene amplification, overexpression, exon 14 skipping, and fusions, have been associated with several cancers including non-small cell lung cancer (NSCLC), colorectal, gastric, and head and neck cancers. In addition, MET amplification is often seen in NSCLC patients with acquired resistance to EGFR inhibitors. Many small molecules and antibodies, such as cabozantinib, tepotinib, and onartuzumab, have been designed to inhibit c-MET and other tyrosine kinases. Many of these drugs only work for a subset of patients with very specific mutations. Finding the right patient for the right drug is one of the biggest challenges facing precision oncology trials. Traditionally, drug companies often would need to go with empirical information, choosing sites that were highly likely to care for patients who might harbor specific mutations and be able to participate in the clinical trials. This often means screening patients for specific MET mutations, with a high chance of failure rate in recruitment. Real-world evidence (RWE) and real-world data (RWD) are emerging areas with primary mandates to repurpose health care data generated in the real world. Specifically for oncology, RWE/RWD has been instrumental in finding the right treatment pathway for patients, identifying novel biomarkers for diseases, finding comorbidities, and identifying patients who are most likely to benefit from experimental drugs. In this presentation we will describe our RWD-based approach to identify patients with MET amplification or exon 14 skipping across cancer types, along with their site or location information. More specifically, we leverage RWD sources with access to records of patients who have consented to share their relevant information. These sources include genomic molecular profiling labs, electronic health records, and data from historical trial sites, with records linked using various integration techniques. We will present our findings with preliminary data, describe the data sources used, outline the technologies leveraged, and conclude with lessons learned. Citation Format: Sivakumar Gowrisankar, Angela Qu. Precise recruitment for precision oncology: RWD use for feasibility and patient identification [abstract]. In: Proceedings of the AACR Special Conference on Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies; Jan 9-12, 2020; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(12_Suppl_1):Abstract nr 04.
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children’s Oncology Group ANBL0532 Study
Authors: Kevin X. Liu, Arlene Naranjo, Fan F. Zhang, Steven G. DuBois, Steve E. Braunstein, Stephan D. Voss, Geetika Khanna, Wendy B. London, John J. Doski, James D. Geiger, Susan G. Kreissman, Stephan A. Grupp, Lisa R. Diller, Julie R. Park, Daphne A. Haas-Kogan
Journal: Journal of Clinical Oncology (2020)

A primary objective of the Children's Oncology Group (COG) ANBL0532 phase III study was to assess the effect of increasing local dose of radiation to a residual primary tumor on the cumulative incidence of local progression (CILP) in patients with high-risk neuroblastoma.Newly diagnosed patients with high-risk neuroblastoma were randomly assigned or assigned to receive single or tandem autologous stem-cell transplantation (SCT) after induction chemotherapy. Local control consisted of surgical resection during induction chemotherapy and radiotherapy after last SCT. Patients received 21.6 Gy to the preoperative primary tumor volume. For patients with incomplete surgical resection, an additional boost of 14.4 Gy was delivered to the gross residual tumor, for a total dose of 36 Gy. CILP (primary end point) and event-free (EFS) and overall survival (OS; secondary end points) were compared with the COG A3973 historical cohort, in which all patients received single SCT and 21.6 Gy without a boost.For all patients in ANBL0532 receiving radiotherapy (n = 323), 5-year CILP, EFS, and OS rates were 11.2% ± 1.8%, 56.2% ± 3.4%, and 68.4% ± 3.2% compared with 7.1% ± 1.4% (P = .0590), 47.0% ± 3.5% (P = .0090), and 57.4% ± 3.5% (P = .0088) for all patients in A3973 receiving radiotherapy (n = 328), respectively. Five-year CILP, EFS, and OS rates for patients in A3973 with incomplete resection and radiotherapy (n = 47) were 10.6% ± 4.6%, 48.9% ± 10.1%, and 56.9% ± 10.0%, respectively. In comparison, 5-year CILP, EFS, and OS rates for patients in ANBL0532 who were randomly assigned or assigned to single SCT and received boost radiotherapy (n = 74) were 16.3% ± 4.3% (P = .4126), 50.9% ± 7.0% (P = .5084), and 68.1% ± 6.7% (P = .2835), respectively.Boost radiotherapy to gross residual tumor present at the end of induction did not significantly improve 5-year CILP. These results highlight the need for new strategies to decrease the risk of locoregional failure.
医生的健康 健康的医生——健康的实践
Authors: Joan, Brewster, 周久顺, 张孔来
Journal: BMJ (2009)

来自3个国家的4个相互联系的研究讨论了有关医生健康的问题（doi：10．1136／bmj．a2004；doi：10．1136／bmj．a2155；doi：10．1136／bmj．a2038；doi：10．1136／bmj．a2098），这几项研究的发表恰逢2008年11月“医生健康国际会议”在伦敦召开。Frank及其同事报告了美国关于医学生使用酒精，以及对使用酒精相关患者进行咨询的研究结果。
Customized mask for patients during facial procedures to maximize the work field
Authors: Ameesha Mahajan, Sanjeev Gupta, Saurabh Chawla, Anshul Mahajan
Journal: Journal of the American Academy of Dermatology (2020)

Laser hair reduction should be withheld according to coronavirus disease 2019 (COVID-19) guidelines. As a result of which, patients with hirsutism are suffering. However, in case of urgency, procedures can be done with appropriate precautions. According to Centers for Disease Control and Prevention guidelines, it is necessary to cover the patient's face with a protective mask. Because a traditional mask covers most of the face, it is not possible to perform a laser procedure when a patient's mask is being worn. The chances of infection are increased if the patient's mask is removed during the procedure. We tried to overcome this problem by making a customized mask. A rectangular piece (6 inches × 8 inches) of appropriate approved fabric was folded twice in half (Fig 1; Video 1, available at http://www.jaad.org). The diagonally opposite sides (the sides other than the free and the folded ends) were then cut to have rounded edges so that the end with folds had a sharper edge. The cloth was then unfolded once, and the fold with the longer length was cut to get 2 similar templates. Elastic bands were attached to the sharper cut ends, and the periphery of both templates was sewed together, leaving the larger (blunter) cut end free. The cloth was again folded like before, and the periphery of the blunter edges was sewed together. The mask was then turned inside out. The mask thus prepared covers the nose and oral apertures very well, without covering other areas of the face (Fig 2; Video 1). We have tried it on our patients for various facial procedures with a great comfort for both the patient and the doctor. The limitation of this mask is that procedures involving upper lip, lower lip, and medial end of the cheek cannot be performed. eyJraWQiOiI4ZjUxYWNhY2IzYjhiNjNlNzFlYmIzYWFmYTU5NmZmYyIsImFsZyI6IlJTMjU2In0.eyJzdWIiOiIyMzFmZGY1ZjAzYzUwODA1ZWJiZWY0ZGZlYWIwOTA5YSIsImtpZCI6IjhmNTFhY2FjYjNiOGI2M2U3MWViYjNhYWZhNTk2ZmZjIiwiZXhwIjoxNzE1MzIzMTUwfQ.VeLFJGPwpFGl0sXUJY-OoEQe0YVI_Y_XTkCja-Snmf4kQLtdnFGc9MjVr89M7RdyZzs_crFECC1q4dGVBbkoEcw3td9b4T6FIpl8WrUvbHcsQBBzXugFXKOkXeXZwA85UPfGPWg0V2aU9_PHDpLCyZckPw8d66AEeFgO85cuvas37sfNhQPTuHUfVNwHTO3zUl2IcHfJ6Jel15o4g9AHOUChjONsUTEVx4YdlbCFsfbXNZvbafPVjYz6oCiKvf4BEU5-twp8cloFj95qaQCs33mctPAEY7lsZ3l6_hrdsEnOULclVzrIEI6cSE1awuWoksfQKGe3xo8VVnW_J8iYrA Download .mp4 (12.24 MB) Help with .mp4 files Video
Recent Advances in Formulating and Processing Biomaterial Inks for Vat Polymerization‐Based 3D Printing
Authors: Wanlu Li, Luis S. Mille, Juan A. Robledo, Tlalli Uribe, Valentin Huerta, Yu Shrike Zhang
Journal: Advanced Healthcare Materials (2020)

Abstract 3D printing and bioprinting have become a key component in precision medicine. They have been used toward the fabrication of medical devices with patient‐specific shapes, production of engineered tissues for in vivo regeneration, and preparation of in vitro tissue models used for screening therapeutics. In particular, vat polymerization‐based 3D (bio)printing as a unique strategy enables more sophisticated architectures to be rapidly built. This progress report aims to emphasize the recent advances made in vat polymerization‐based 3D printing and bioprinting, including new biomaterial ink formulations and novel vat polymerization system designs. While some of these approaches have not been utilized toward the combination with biomaterial inks, it is anticipated their rapid translation into biomedical applications.
HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma
Authors: Yixuan Li, Xiangyang Zhang, Shaoqi Zhu, Eden A. Dejene, Weiqun Peng, Antonia Sepulveda, Edward Seto
Journal: Cancer Research (2020)

Activation of oncogenic KRAS is the most common driving event in lung adenocarcinoma development. Despite the existing rationale for targeting activated KRAS and its downstream effectors, the failure of clinical trials to date indicates that the mechanism of KRAS-driven malignancy remains poorly understood. Here we report that histone deacetylase 10 (HDAC10) might function as a putative tumor suppressor in mice carrying a spontaneously activated oncogenic
Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus
Authors: Amir H. Lebastchi, Arvin K. George, Thomas J. Polascik, Jonathan Coleman, Jean de la Rosette, Baris Turkbey, Bradford J. Wood, Michael A. Gorin, Abhinav Sidana, Sangeet Ghai, Kae Jack Tay, John F. Ward, Rafael Sanchez-Salas, Berrend G. Muller, Bernard Malavaud, Pierre Mozer, Sebastien Crouzet, Peter L. Choyke, Osamu Ukimura, Ardeshir R. Rastinehad, Peter A. Pinto
Journal: European Urology (2020)
John Nicolas Rea: GP and reluctant peer
Authors: John Illman
Journal: BMJ (2020)

Photo credit: Judith Rea

The north London GP Nicolas “Nic” Rea spent a year agonising over whether to take up his hereditary seat in the House of Lords. He feared that it might represent a savage betrayal of his principles, but serendipity played the decisive hand.

During a train journey from Birmingham to London, Rea’s son, Quentin, met, by chance, the former Labour Cabinet minister Tony Benn; Joan Lestor MP; and the anti-war activist Lord Fenner Brockway. He told them about his father’s dilemma.

Writing to Rea, Brockway said, “I promised to let you know that many of us who are reluctant peers try to use the chamber to urge the causes in which we believe. I think we have made some success of it. I don’t know whether this will make you reconsider your attitude, but we would very much like to have you with us.”

Succeeding his uncle, a merchant banker and a Liberal leader in the House of Lords, in 1981, Rea used his peerage for nearly 40 years to promote public health—and was briefly a Labour front bench spokesman.

His background may explain his initial ambivalence to the Lords. His mother was the influential sculptor Betty Rea. Deeply committed to anti-fascist, left wing politics, she was an active member of the Communist Party …
Addressing Health Disparities Among Minority Populations
Authors: Consuelo H. Wilkins, Suzanne E. Schindler, John C. Morris
Journal: JAMA Neurology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Diabetes Epidemiology in the COVID-19 Pandemic
Authors: Elizabeth Selvin, Stephen P. Juraschek
Journal: Diabetes Care (2020)

Diabetes has been identified as an important risk factor for mortality and rates of progression to acute respiratory distress syndrome (ARDS) in hospitalized patients with coronavirus disease 2019 (COVID-19). However, many recent reports on this topic reflect hurried approaches and have lacked careful epidemiologic design, conduct, and analysis. Features of prior studies have posed problems for our understanding of the true contribution of diabetes and other underlying comorbidities to prognosis in COVID-19. In this Perspective, we discuss some of the challenges of interpreting the current literature on diabetes and COVID-19 and discuss opportunities for future epidemiologic studies. We contend that the COVID-19 pandemic is a defining moment for the field of epidemiology and that diabetes epidemiology should play a significant role.
AB1310-HPR EFFECTS OF INSTRUMENT-ASSISTED SOFT TISSUE MOBILIZATION ON FROZEN SHOULDER: A RANDOMIZED CONTROLLED TRIAL
Authors: E. Kaya Mutlu, T. Birinci, S. Kilic
Journal: Annals of the Rheumatic Diseases (2020)

Background: Frozen shoulder has a greater incidence, more severe course, and resistance to treatment in patients. Management is based on the underlying cause of pain and stiffness. Joint mobilization has been reported to improve joint range of motion in frozen shoulder. However, there is no information regarding the effect of instrument-assisted soft tissue mobilization (IASTM) in frozen shoulder. We proposed that there would be no significant difference between the two manual physical therapy techniques with relatively similar treatment effects in the frozen shoulder. Objectives: The aim of this randomized controlled study was to compare the effectiveness of IASTM and joint mobilization in the treatment of patients with frozen shoulder. Methods: Thirty patients with phase II frozen shoulder (mean age 50,9 years, age range 39–65 years) were randomly assigned to one of the two treatment groups: Group I received joint mobilization combined with manual stretching exercise and Group II received IASTM with manual stretching exercise (two days per week for six weeks) (Figure 1). The pain level was evaluated with a visual analogue scale (VAS) and the active range of motion (ROM) was measured with a universal goniometer. The Disabilities of the Arm, Shoulder and Hand score and the Constant-Murley score were used for functional assessment. The assessments were performed at baseline and after the 6-week intervention. Figure 1. Instrument-Assisted Soft Tissue Mobilization Results: Both groups had a significant decrease in pain according to VAS and a significant increase in ROM and function level (p&lt;0.05). After the 6-week intervention, improvement of shoulder abduction ROM in Group I was found significantly higher than Group II (p=0.01), on the other hand, Constant-Murley score in Group II was found significantly higher compared to Group I (p=0,001). Conclusion: Our results supported the hypothesis that either joint mobilization or IASTM, performed in addition to stretching exercise, provided similar improvements in pain levels in patients with the frozen shoulder. References: [1]Kelley MJ, Shaffer MA, Kuhn JE, Michener LA, Seitz AL, Uhl TL, et al. Shoulder Pain and Mobility Deficits: Adhesive Capsulitis, J Orthop Sports Phys Ther, 2013:43:1-31. [2]Celik D, Kaya Mutlu E. Does Adding Mobilization to Stretching Improve Outcomes for People with Frozen Shoulder? A Randomized Controlled Clinical Trial, Clin Rehab, 2016: 30(8): 786-794. [3]Iked N, Otsuka S, Kawanishi Y, Kawakami Y. Effects of Instrument-Assisted Soft Tissue Mobilization on Musculoskeletal Properties, Med Sci Sports Exerc, 2019:51(10): 2166-2172. Disclosure of Interests: None declared
Soundings: Class list
Authors: Colin Douglas
Journal: BMJ (1999)

It came in the kind of envelope that tends to lie unopened for a day or two: an alphabetical list of about 150 names and addresses on several sheets of pale blue A4. It might have been dull, something for the waste paper basket.

It wasn’t. I glanced at it, read it, read it again, and settled to enjoy it, reflect on it, ponder the questions it raised, relish its nuances, and then, over a couple of weeks, came back to it a few more times to attempt to decode it, perhaps at too many levels.

Where are they now? Two at least have no known address. No fewer than eight are dead, one poor chap dead and misspelt too. The rest of us are scattered wide: about half around England, a third or so here in Scotland, the remainder split equally between the United States and what we thought of then as the British Commonwealth.

Addresses are intriguing. What can be made of not having one? There is more palpable comfort in the occasional Old Rectory or the house with a capital H. And is there something cautious or mistrustful about opting for the neutrality of a professional location (Cardiology Associates, 2108 29th Avenue, etc)?

Never mind where we are. Who are we now? Obviously, we are the people who graduated together 30 years ago, but how little of current reality that conveys. Scattered clues half help. Women’s surnames may or may not change as marriages come and go; men are sheltered from such scrutiny. Addresses including bits of Welsh or Maori evoke a reflex sympathy, possibly uncalled for. Deep rurality suggests general practice or perhaps—no disrespect intended—retirement.

Titles help too, in their way. As you would expect, doctors predominate. No lords yet, but there is a lady, the wife of a life peer. Misters are few, outnumbered now by professors, some in the strangest places.

There is, of course, an impending reunion—details enclosed—but that is for the minority: broadly the active, the affluent, the successful. The list is far more daunting: all of us—from the brilliant to the merely dogged; the solitary, the gregarious, and the frankly drunk or mad; the living and the dead, too—are mustered again as once we were in medical school, alphabetically and on a few sheets of A4. Time shrinks and spreads and shrinks again, as lives speed suddenly from the dissecting room to the grave.
Abstract B29: Intraoperative identification of critical vascular landmarks of the lateral oropharynx and tongue base using transoral robotic ultrasound (TORUS)
Authors: Wen P. Liu, F. Chris Holsinger, Varun Vendra
Journal: Clinical Cancer Research (2020)

Abstract Transoral robotic surgery (TORS) is an expanding domain of minimally invasive surgery, which has been employed since 2009 in the United States primarily for the management of upper aerodigestive tract tumors (1). Tongue base reduction is an emergent application of TORS in obstructive sleep apnea (2). The technique uses the da Vinci surgical system (Intuitive Surgical, Sunnyvale, CA, USA) to deliver a camera and instruments on three robotic arms. Identification of large-caliber blood vessels emanating from the external carotid artery is a critical step in TORS for tongue base and lateral oropharynx disease. Specifically, control of the lingual artery and facial artery branches is necessary for safe surgical dissection (3). Previously, the use of ultrasound has been described in TORS for the intraoperative localization of retropharyngeal lymph nodes (4-6). One case series in the literature has described the use of a handheld ultrasound probe in TORS for pharyngeal and base of tongue tumors (7). We describe the use of a novel miniaturized ultrasound probe (Mindray North America, San Jose, CA, USA) capable of being manipulated by the da Vinci arm to allow intraoperative transoral robotic ultrasonography (TORUS). The ergonomics of this system was evaluated in human cadavers, followed by an efficacy trial in a porcine model. Two surgeons, one experienced (FCH) and one novice (VV), performed ultrasound-guided identification of the lingual and buccal arteries. Time to identification was measured. Mean time in seconds for the localization of the buccal artery was 53.0 for the experienced robotic surgeon versus 27.5 for the novice surgeon (p=0.10), and 55.0 versus 268.0, respectively, for the lingual arteries (p=0.003). Herein, we show the feasibility of TORUS to identify the large-caliber blood vessels of the oral cavity and oropharynx during TORS. This platform may allow for safer dissection, without a significant increase in operative time or need to interrupt the robotic setup. Future directions include human clinical trials, measurement of tumor volume, depth of invasion, and identification of additional surgical landmarks. Citation Format: Wen P. Liu, F. Chris Holsinger, Varun Vendra. Intraoperative identification of critical vascular landmarks of the lateral oropharynx and tongue base using transoral robotic ultrasound (TORUS) [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; 2019 Apr 29-30; Austin, TX. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(12_Suppl_2):Abstract nr B29.